A Phase 2a, Randomized, Open-Label Study in Patients with Chronic Hepatitis C Viral Infection to Assess the Safety, Tolerability, Pharmacodynamics, and Antiviral Activity of ANA773 Tosylaat Administered with Ribaviri
Phase 2
Withdrawn
- Conditions
- hepatitis Cjaundice10047438
- Registration Number
- NL-OMON35795
- Lead Sponsor
- Anadys Therapeutics Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 6
Inclusion Criteria
Hepatitis C, genotype 1
IL28B genotypic polymorphism CT
naïve to or have relapsed from prior pegylated interferon-alpha based therapy
Age between 18 - 65 year of each
Exclusion Criteria
Pregnant or lactating females;
patient previously treated with experimental drugs for HCV
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Pharmacodynamics:<br /><br>viral load Hepatitis C.<br /><br>Safety: adverse events, vital signs, ECG-parameters, laboratory parameters,<br /><br>physical examination.</p><br>
- Secondary Outcome Measures
Name Time Method <p>N/A</p><br>